227 related articles for article (PubMed ID: 19150343)
1. Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions.
Bock KW; Köhle C
Biochem Pharmacol; 2009 May; 77(9):1458-65. PubMed ID: 19150343
[TBL] [Abstract][Full Text] [Related]
2. Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum.
Meech R; Mackenzie PI
Arch Biochem Biophys; 1998 Aug; 356(1):77-85. PubMed ID: 9681994
[TBL] [Abstract][Full Text] [Related]
3. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
Miners JO; Knights KM; Houston JB; Mackenzie PI
Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
[TBL] [Abstract][Full Text] [Related]
4. Kinetic properties of UDP-glucuronosyltransferase(S) in different membranes of rat liver cells.
Antoine B; Magdalou J; Siest G
Xenobiotica; 1984 Jul; 14(7):575-9. PubMed ID: 6438924
[TBL] [Abstract][Full Text] [Related]
5. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.
Miners JO; Mackenzie PI; Knights KM
Drug Metab Rev; 2010 Feb; 42(1):196-208. PubMed ID: 19795925
[TBL] [Abstract][Full Text] [Related]
6. A functional role for histidyl residues of the UDP-glucuronic acid carrier in rat liver endoplasmic reticulum membranes.
Battaglia E; Radominska-Pandya A
Biochemistry; 1998 Jan; 37(1):258-63. PubMed ID: 9425046
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
Williams JA; Hyland R; Jones BC; Smith DA; Hurst S; Goosen TC; Peterkin V; Koup JR; Ball SE
Drug Metab Dispos; 2004 Nov; 32(11):1201-8. PubMed ID: 15304429
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
Iyanagi T
Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904
[TBL] [Abstract][Full Text] [Related]
9. Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases.
Riches Z; Collier AC
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):949-65. PubMed ID: 25797307
[TBL] [Abstract][Full Text] [Related]
10. Structure of UDP-glucuronosyltransferases in membranes.
Radominska-Pandya A; Ouzzine M; Fournel-Gigleux S; Magdalou J
Methods Enzymol; 2005; 400():116-47. PubMed ID: 16399347
[TBL] [Abstract][Full Text] [Related]
11. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators.
Knights KM; Miners JO
Drug Metab Rev; 2010 Feb; 42(1):63-73. PubMed ID: 19780654
[TBL] [Abstract][Full Text] [Related]
12. UDP-glucuronosyltransferases and clinical drug-drug interactions.
Kiang TK; Ensom MH; Chang TK
Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
[TBL] [Abstract][Full Text] [Related]
13. Glucuronate, the precursor of vitamin C, is directly formed from UDP-glucuronate in liver.
Linster CL; Van Schaftingen E
FEBS J; 2006 Apr; 273(7):1516-27. PubMed ID: 16689937
[TBL] [Abstract][Full Text] [Related]
14. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases.
Kaivosaari S; Finel M; Koskinen M
Xenobiotica; 2011 Aug; 41(8):652-69. PubMed ID: 21434773
[TBL] [Abstract][Full Text] [Related]
15. [Recent data on the metabolism of drugs by UDP-glucuronosyltransferases and sulfotransferases (author's transl)].
Batt AM; Magdalou J; Martin N; Lepage C; Kiffel L; Siest G
Ann Biol Clin (Paris); 1980; 38(1):35-47. PubMed ID: 6769373
[TBL] [Abstract][Full Text] [Related]
16. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases.
Tong Z; Li H; Goljer I; McConnell O; Chandrasekaran A
Drug Metab Dispos; 2007 Dec; 35(12):2203-10. PubMed ID: 17875670
[TBL] [Abstract][Full Text] [Related]
17. The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells.
Burchell B; Baird S; Coughtrie MW
Princess Takamatsu Symp; 1990; 21():263-75. PubMed ID: 1966888
[TBL] [Abstract][Full Text] [Related]
18. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates.
Fujiwara R; Nakajima M; Yamanaka H; Katoh M; Yokoi T
Drug Metab Dispos; 2008 Feb; 36(2):361-7. PubMed ID: 17998297
[TBL] [Abstract][Full Text] [Related]
19. Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights.
Tripathi SP; Bhadauriya A; Patil A; Sangamwar AT
Drug Metab Rev; 2013 May; 45(2):231-52. PubMed ID: 23461702
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins.
Green MD; Tephly TR
Drug Metab Dispos; 1998 Sep; 26(9):860-7. PubMed ID: 9733664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
